This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Mogamulizumab for previously treated mycosis fungoides and Sezary syndrome

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Cutaneous T-cell lymphoma (CTCL) is a rare non-Hodgkin lymphoma (NHL) that primarily arises in the skin but may involve the viscera, lymphatic system

  • mycosis fungoides is the most common subtype of CTCL

NICE state (1):

  • Mogamulizumab is recommended, within its marketing authorisation, as an option for treating Sezary syndrome (SS) in adults who have had at least 1 systemic treatment
  • Mogamulizumab is recommended as an option for treating mycosis fungoides (MF) in adults, only if:
    • their condition is stage 2B or above and
    • they have had at least 2 systemic treatments

Notes (2,3):

  • MF is the most common subtype of CTCL, with 1,620 incidences reported in 2016 in the United States, and is often characterized by patches, plaques, and erythroderma. SS is a much more rare and aggressive leukemic variant of CTCL, with an incidence of 70 in the same year (3)
  • study evidence evaluated mogamulizumab (a novel CCR4 humanized monoclonal antibody) , in relapsed/refractory MF and SS, show a meaningful progression free survival (PFS) benefit
  • the Phase III MAVORIC study compared mogamulizumab to vorinostat, an FDA approved drug for this indication, in 372 patients
    • mogamulizumab was found to have a superior PFS with a median of 7.7 months compared to 3.1 months in the vorinostat arm, with a hazard ratio of 0.53, p<0.001
    • mogamulizumab was well tolerated with the most common AE being infusion-related reactions (32%), drug rash (20%), diarrhea (23%), and fatigue (22%)
  • use of mogamulizumab up to 50 days prior to allogeneic hematopoietic stem cell transplantation has been associated with an increased risk of severe acute graft-vs.-host disease, steroid-refractory graft-vs.-host disease, and mortality (3)

Reference:

  • NICE (December 2021). Mogamulizumab for previously treated mycosis fungoides and Sezary syndrome
  • Blackmon AL, Pinter-Brown L. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection. Drug Des Devel Ther. 2020;14:3747-3754. Published 2020 Sep 16. doi:10.2147/DDDT.S185896
  • Watson S, Marx JB. Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma. J Adv Pract Oncol. 2019;10(8):883-888. doi:10.6004/jadpro.2019.10.8.10

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.